Purpose
To evaluate RGD-conjugated HFn-iron oxide nanoparticles for enhanced in vivo MRI detection of murine carotid atherosclerosis.
Methods

1) Mice
Fourteen FVB mice underwent left carotid ligation after 4 weeks of high-fat diet and diabetes induction by streptozotocin.
2) RGD-conjugated HFn-iron oxide nanoparticles
Using the recombinant human heavy-chain ferritin protein cage, HFn was genetically engineered to display 24 copies of an RGD-4C peptide (CDCRGDCFC) on the exterior surface of the protein cage. Magnetite (Fe 3 O 4 ) was encapsulated in interior cavities of RGD-conjugated HFn (RGD + HFn) and non-targeted HFn (RGD -HFn) at loading factors of 5000Fe per cage, giving R2 values of 93 mM -1 s -1 (magnetite diameter: 5-7nm, exterior diameter: 12nm). The injected dose was adjusted to 25mgFe/kg.
3) MRI
Two weeks post ligation, mice were imaged on a wholebody 3T MRI scanner (Signa HDx, GE Healthcare) with a phased array mouse coil (RAPID MR International), using a gradient echo sequence (TR/TE=100ms/10ms, slice thickness=1.0mm, FOV=3cm, matrix=256x256, FA=60, NEX=10). Mice were then injected with either RGD + (n=7) or RGD -(n=7) HFn nanoparticles, followed by MRI at 24 and 48 hours post injection. The nanoparticle accumulation was assessed by measuring the extent of T2*-induced reduction in carotid lumen size (% reduction of carotid lumen area).
4) Histology
Perl's iron staining was performed to identify accumulation of the nanoparticles in the carotid lesions.
Results
Both RGD
+ and RGD -HFn nanoparticles caused a reduction in lumen size of the ligated left carotid arteries at 48 hrs due to T2* signal loss (p<0.001 vs. preinjection, Figures 1, 2 ), but the effect was significantly greater with RGD + HFn (p=0.01 vs. RGD -HFn). There was no significant lumen reduction in the non-ligated (control) right carotid arteries. Perl's iron staining confirmed greater accumulation of RGD + HFn in the lesion compared to RGD -HFn, primarily in neointimal macrophages (Figure 3 ).
Conclusions
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